San Francisco startup Construction Therapeutics is likewise working on an oral, once-everyday GLP-1 drug named GSBR-1290—the drug surpassed Wall Street’s expectations in June when a mid-phase study showed regular weight loss of close to 6% and it ideas to begin A different mid-stage